Lantheus Medical Imaging Announces Manufacturing and Supply Agreements With Jubilant HollisterStier LLC for Cardiolite®and Neurolite®
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced new manufacturing and supply agreements with Jubilant HollisterStier LLC (JHS). Under separate agreements, JHS will manufacture Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) products and Neurolite®(Kit for the Preparation of Technetium Tc99m Bicisate for Injection), each for an initial term of five years and each with an option to renew for an additional five years thereafter. In February 2012, Lantheus entered a similar agreement with JHS to manufacture DEFINITY®Vial for (Perflutren Lipid Microsphere) Injectable Suspension. Cardiolite®and Neurolite® are technetium-based radiopharmaceutical imaging agents used in single-photon emission computed tomography, or SPECT. DEFINITY® is an ultrasound contrast agent for use in patients with suboptimal echocardiograms.